Definium Therapeutics (DFTX) Net Income towards Common Stockholders (2021 - 2026)

Definium Therapeutics (DFTX) has 6 years of Net Income towards Common Stockholders data on file, last reported at -$77.1 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 230.21% year-over-year to -$77.1 million in Q1 2026; TTM through Mar 2026 was -$237.5 million, a 206.01% decrease from a year earlier, with the FY2025 full-year figure at -$183.8 million, down 69.12% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$77.1 million, down from -$50.4 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for DFTX reached as high as -$5.1 million in Q4 2022 and fell as low as -$77.1 million in Q1 2026.
• Historically, Net Income towards Common Stockholders has averaged -$30.9 million across 5 years, with a median of -$23.3 million in 2025.
• Across the five-year window, Net Income towards Common Stockholders jumped 79.0% in 2024 and tumbled 630.17% in 2025, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$5.1 million in 2022, then slumped by 305.93% to -$20.8 million in 2023, then slumped by 66.93% to -$34.7 million in 2024, then tumbled by 45.18% to -$50.4 million in 2025, then plunged by 52.86% to -$77.1 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$77.1 million in Q1 2026, -$50.4 million in Q4 2025, and -$67.3 million in Q3 2025.